GlassScriptPhysician profile
Philip Strenger
NPI 1528074648
$11,180.19
in general payments reported to CMS, 2019-2025
24 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $1,334 · 2021: $1,468 · 2022: $1,282 · 2023: $2,203 · 2024: $1,790 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,474 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,474.11 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,043.57 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,516.58 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,483.90 | 2019-2025 | |
| Amgen INC. | $961.56 | 2019-2023 | Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $894.43 | 2022-2025 | Sotyktu |
| Incyte Corporation | $542.58 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $505.41 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $437.94 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $348.54 | 2023-2024 | Vtama |
| Genzyme Corporation | $345.12 | 2019-2025 | |
| Lilly USA, LLC | $335.54 | 2019-2024 | Olumiant, Taltz |
| Galderma Laboratories, L.P. | $329.71 | 2020-2025 | Aklief |
| Sun Pharmaceutical Industries INC. | $256.90 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $238.15 | 2020-2021 | |
| Ucb, INC. | $226.40 | 2019-2025 | Bimzelx, Cimzia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $197.32 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $164.67 | 2019-2021 | |
| Pfizer INC. | $137.14 | 2019-2021 | |
| Journey Medical Corporation | $95.85 | 2020-2022 | |
| Lnhc, INC | $40.53 | 2025 | Zelsuvmi |
| Aclaris Therapeutics, INC. | $22.34 | 2019 | |
| Almirall LLC | $21.16 | 2021 | |
| Genentech USA, INC. | $17.80 | 2019 | |
| Organon LLC | $17.05 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Strenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.